ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
Rhea-AI Summary
ALX Oncology (NASDAQ: ALXO) appointed Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026. Mr. Knight brings more than 30 years of biopharma and oncology experience across clinical development, regulatory affairs, and operations.
The company said his hire aims to strengthen development capabilities ahead of expected catalysts for evorpacept and ALX2004 over the next 12–18 months and to support late‑stage development and commercialization readiness.
AI-generated analysis. Not financial advice.
Positive
- Appointment of Jeff Knight as CDOO effective April 13, 2026
- 30+ years of biopharma and oncology development experience
- Track record advancing programs from early development to commercialization
- Leadership focused on upcoming evorpacept and ALX2004 catalysts (12–18 months)
Negative
- None.
News Market Reaction – ALXO
On the day this news was published, ALXO gained 2.94%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.3% during that session. Argus tracked a trough of -9.0% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $250.06M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ALXO was flagged with an upward bias while momentum peers CUE and PDSB moved down (-11.64% and -3.70%). With 0 peers in the same direction and 2 moving lower, trading appeared stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 27 | Earnings and update | Positive | -10.2% | Full-year 2025 results, runway to 1H 2028, and clinical milestone outlook. |
| Feb 19 | Investor conferences | Positive | +12.1% | Participation in three Q1 2026 investor events and webcast access details. |
| Feb 19 | Earnings date notice | Neutral | +12.1% | Announcement of Feb 27, 2026 earnings release and conference call timing. |
| Jan 30 | Equity offering | Negative | +10.8% | Pricing of large underwritten stock and pre-funded warrant offering to raise capital. |
| Jan 30 | Clinical data update | Positive | +10.8% | Phase 1b/2 data showing CD47 expression predicts response to evorpacept combo. |
News tied to financings and earnings has produced mixed reactions, with positive clinical and conference updates more often aligning with upside moves while some balance sheet and offering events saw negative or contrary reactions.
Over the last few months, ALXO has reported key financings, clinical data and corporate updates. On Jan 30, 2026, positive breast cancer data and an underwritten offering coincided with notable price gains. Subsequent conference and earnings-date announcements on Feb 19, 2026 also saw upside reactions. However, the detailed Q4/FY 2025 earnings and corporate update on Feb 27, 2026 prompted a -10.21% move, highlighting that seemingly constructive financial and pipeline progress has not always translated into immediate share strength. Today’s leadership appointment fits within this ongoing maturation of the organization.
Market Pulse Summary
This announcement highlighted ALXO’s effort to bolster execution ahead of multiple evorpacept and ALX2004 milestones expected over the next 12 to 18 months by appointing a veteran leader with more than 30 years in oncology and clinical development. Recent history shows mixed share reactions to earnings, financings, and data releases, so investors may focus less on the title change and more on upcoming clinical readouts, capital allocation, and how effectively the expanded leadership team advances late‑stage development.
Key Terms
oncology medical
clinical development medical
biostatistics medical
epidemiology medical
AI-generated analysis. Not financial advice.
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026.
“Jeff is a highly accomplished leader with deep expertise across clinical development and operations, and a strong track record of both advancing innovative therapies through critical stages of growth and advancing companies of our stage through late-stage development and commercialization,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “We anticipate several important catalysts in the next 12 to 18 months with our evorpacept and ALX2004 clinical programs. Jeff’s leadership will be instrumental in strengthening our development capabilities and operational infrastructure to support high-quality execution and deliver on these upcoming milestones.”
Mr. Knight brings more than 30 years of experience across the biopharmaceutical industry, with demonstrated success advancing programs from early development through commercialization, including multiple oncology programs. Most recently, he served as Chief Development and Operating Officer at Crinetics Pharmaceuticals, where he was responsible for clinical development, portfolio strategy, and corporate operations. Prior to joining Crinetics Pharmaceuticals, Mr. Knight held senior leadership roles at Poseida Therapeutics, Halozyme Therapeutics, Amgen and Onyx Pharmaceuticals, where he led development and operational functions within these organizations. Earlier in his career, he held several roles at Genentech, gaining extensive experience in oncology clinical development and regulatory affairs.
“ALX Oncology is entering a critical phase of growth, with multiple opportunities to advance its pipeline and build a scalable organization,” said Mr. Knight. “I am incredibly excited about ALX’s clinical programs and data and look forward to working with the team to ensure strategic development and operational excellence as the company advances toward key clinical and corporate milestones.”
Mr. Knight holds a Master of Public Health in Biostatistics and Epidemiology and a Bachelor of Arts in Psychology from the University of Oklahoma, as well as a Bachelor of Science in Nursing from the University of Kansas.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (SEC), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028
